When administered, the peptide preferentially accumulates in adipose tissue, where it interacts with beta-3 adrenergic receptors on fat cell membranes and initiates metabolic signaling cascades
Last reviewed: May 12, 2026 Last updated: May 12, 2026 Written by: Jay Hastings , CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
THEY ARE NOT A DRUG, FOOD, OR COSMETICS AND SHOULD NOT BE TREATED AS SUCH
For a sense of how research observations with this compound are typically framed over time, see the 5-Amino-1MQ results timeline
consistent ~12-15% weight loss at 68 weeks Compound Tirzepatide (Zepbound) Class GIP/GLP-1 dual agonist FDA Status FDA-approved for chronic weight management Evidence Strength Phase 3 RCTs